86 SKIN MICROBIOME
housekeeping enzyme that helps to break down large molecule called glucocerebroside into a sugar (glucose) and a simple fat molecule (ceramide). SPTLC (Serine palmitoyltransferase) is an
enzyme that responds to the increase in ceramide generation.
100
Protocol Human epidermal keratinocytes (HaCaT) were incubated for 24 hours (at 37ºC, 5% CO2
) in the presence of 2% mushroom
hydrolysate with S. aureus cultured medium (SACM) 36µg/ml. The expression levels of mRNA were analysed by RT-PCR. AA: Ascorbic Acid.
Results The study focused on epidermal lipid enhancement by increasing expression of skin barrier factors, and showed that with the use of the active, aSMase registered an increase of 27.7%; GBA an increase of 36.2 %, while SPTLC saw an increase of 18.5%.
Immune barrier (Fig 5) The immune barrier comprises immune cells, and senses danger signals and protects skin from the external harmful factors by providing cytokines, antimicrobial peptides, etc.
Protocol Human epidermal keratinocytes (HaCaT) were incubated for 24 hours (at 37ºC, 5% CO2
) in the presence of 2% mushroom
hydrolysate with S. aureus cultured medium (SACM) 36µg/ml. The expression levels of mRNA were analysed by RT-PCR. PIM: Pimecrolimus. TLR6 (Toll-like receptor 6) plays a
fundamental role in pathogen recognition and activation of innate immunity. hBD2 (Human Β-defensin-2) & hBD3
(Human Β-defensin-3) are known as antimicrobial peptides.
Results The study looked at signs of skin immunity improvement by increasing expression of immunity factors, and the results are as follows: l TLR6 + 18.3% l hBD2 + 21.2% l hBD3 + 19.7 %
In vivo: Skin roughness improvement Method In order to evaluate skin roughness improvement, the test subject applied 2% mushroom hydrolysate cream for 2 weeks, and the skin’s roughness was analysed with Antera 3D (Miravex Limited). Using 3D imaging, we could see that
after 2 weeks, skin roughness had improved by: + 18% on average and up to + 82%
PERSONAL CARE ASIA PACIFIC 80 60 40 20 0 SACM – Control
+ –
+ 2% ECOMUSHLYTE Figure 5: Skin immunity improvement by increasing expression of immunity factors.
In vivo: Skin density enhancement Method To evaluate skin density enhancement, the test subject applied 2% mushroom hydrolysate cream for 2 weeks and density in dermis and epidermis was analysed with Dermalab Combo Ultrasound (Cortex Technology). From the in vivo test using ultrasound, it
was possible to determine that enhancement of skin density was shown + 9.7% on average and up to + 40.8%.
Conclusion Ecomushlyte, a hydrolysate of Reishi mushroom (Ganoderma lucidum), Maitake
mushroom (Grifola frondosa) and Shiitake Mycelium (Lentinus edodes) produced with a unique green extraction method, offers efficacy across a wide range of potential formulations, including: Areas of efficacy include: cell
protection, skin pH readjustment, epidermal lipid enhancement, skin immunity improvement, skin roughness improvement, and skin density enhancement. The ingredient is supplied in two
versions: G and HD. HD is formulated with the addition of hexanediol and the recommended level for both versions is 2%.
PC November 2020 +
10uM PIM
80 60 40 20 0 SACM – Control
+ –
+ 2% ECOMUSHLYTE +
50ppm AA
Figure 4: Epidermal lipid enhancement by increasing expression of skin barrier factors. n TLR6 n hBD2 n hBD3 140 120 100 n aSMase n GBA n SPTLC 140 120
Relative expression (%)
Relative expression (%)
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96